We are your reference in research and development in biotechnology for neurological diseases
Araclon is a company specializing in Alzheimer's Disease (AD). It emerged in 2004 as a spin-off of the University of Zaragoza. Since 2012, and coinciding with the incorporation of the multinational company Grifols as a shareholder, Araclon Biotech has consolidated its position as a pioneering company in the development of projects for the diagnosis and treatment of Alzheimer's Disease.
Early diagnosis of Alzheimer
At Araclon Biotech we have developed a test for the analysis of β-amyloid peptides in human plasma that have demonstrated their potential to help identify people who are cognitively normal, but who already have AD-related pathological changes in their brains. The company currently has centralized laboratories in Zaragoza, Spain (headquarters) from where we offer ABtest-Service for the determination of these peptides in human plasma.
Immunotherapy
At Araclon Biotech we are also striving to prevent the disease at an early stage by developing active immunotherapies (vaccines) against β-amyloid peptides.
One of our vaccines (ABvac40) has recently completed phase II of the clinical trial.
Intellectual property
As a result of this research work, Araclon Biotech's intellectual property encompasses several patent families that protect our diagnostic assays (IP ABtest42/40, IP ABtestMS) and our active immunotherapies (IP ABvac40, IP ABvac42).
Vocation for science
Our history
Find out how Dr Manuel Sarasa founded Araclon Biotech and the company's journey to where it is now.
Communications to partners
Access the information intended for the partners of Araclon Biotech.
How can we help you?
Contact the Araclon Biotech team.